{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:02:41Z","timestamp":1784016161153,"version":"3.55.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Vector-Borne and Zoonotic Diseases"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Public surveillance of Lyme borreliosis (LB) occurs in 9 out of 16 federal states of Germany and remains a critical facet of disease epidemiology and trends. We describe the incidence, time trends, seasonality, and geographic distribution of LB in Germany using publicly reported surveillance data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We obtained LB cases and incidence (2016\u22122020) from the online platform SurvStat@RKI 2.0, maintained by the Robert Koch Institute (RKI). Data included clinically diagnosed and laboratory-confirmed LB reported by nine out of 16 federal states of Germany where LB notification is mandatory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>During 2016\u22122020, the nine federal states reported 63,940 LB cases, of which 60,570 (94.7%) were clinically diagnosed, and 3370 (5.3%) also had laboratory confirmation, with an average of 12,789 cases annually. Incidence rates were mostly stable over time. The average annual LB incidence was 37.2\/100,000 person-years and varied by spatial level, ranging from 22.9 to 64.6\/100,000 person-years among nine states; from 16.8 to 85.6\/100,000 person-years among 19 regions; and from 2.9 to 172.8\/100,000 person-years among 158 counties. Incidence was lowest among persons 20\u201324 years old (16.1\/100,000 person-years) and highest among those 65\u201369 years old (60.9\/100,000 person-years). Most cases were reported between June and September, with a peak in July of every year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The risk of LB varied substantially at the smallest geographic unit and by age group. Our results underscore the importance of presenting LB data at the most spatially granular unit and by age to allow implementation of efficient preventive interventions and reduction strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/vbz.2022.0046","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T11:44:14Z","timestamp":1681818254000},"page":"237-246","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Incidence of Lyme Borreliosis in Germany: Exploring Observed Trends Over Time Using Public Surveillance Data, 2016\u20132020"],"prefix":"10.1177","volume":"23","author":[{"given":"Jozica","family":"Skufca","sequence":"first","affiliation":[{"name":"Epidemiology &amp; Pharmacovigilance, P95, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao Mai Phuong","family":"Tran","sequence":"additional","affiliation":[{"name":"Epidemiology &amp; Pharmacovigilance, P95, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Brestrich","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pilz","sequence":"additional","affiliation":[{"name":"Pfizer Global Medical Affairs, Vaccines, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vyse","sequence":"additional","affiliation":[{"name":"Vaccines Medical Affairs, Pfizer Ltd., Walton Oaks, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudius","family":"Malerczyk","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendwas","family":"Dzingina","sequence":"additional","affiliation":[{"name":"Patient Health and Impact, Chief Business Office, Pfizer Inc, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Begier","sequence":"additional","affiliation":[{"name":"Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Blum","sequence":"additional","affiliation":[{"name":"Epidemiology &amp; Pharmacovigilance, P95, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Riera-Montes","sequence":"additional","affiliation":[{"name":"Epidemiology &amp; Pharmacovigilance, P95, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford D.","family":"Gessner","sequence":"additional","affiliation":[{"name":"Vaccines Medical Development &amp; Scientific\/Clinical Affairs, Pfizer Inc, Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0728-876X","authenticated-orcid":false,"given":"James H.","family":"Stark","sequence":"additional","affiliation":[{"name":"Vaccines Medical Development &amp; Scientific\/Clinical Affairs, Pfizer Inc, Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"e_1_3_6_2_1","unstructured":"Akmatov MK Holstiege J Dammertz L Kohring C et al. Nationwide and local figures on the morbidity of Lyme disease in Germany based on panels doctors accounting data 2010 to 2019. Central Institute for the Kassena Medical Care in Germany (Zi). Supply Atlas Report No. 21\/06 [in German]. Berlin; 2021."},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9091872"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jme\/tjw116"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1089\/vbz.2022.0071"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-018-3417-1"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041321"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-017-2590-x"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33136-0"},{"key":"e_1_3_6_10_1","unstructured":"Federal Association for Statutory Health Insurance Physicians (KBV). More and more practices are using cameras\u2014Number of video consultations has risen to over one million. 2021. Available at: https:\/\/www.kbv.de\/html\/1150_50419.php"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084758"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-008-1060-y"},{"key":"e_1_3_6_13_1","first-page":"Doc14","article-title":"Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society","volume":"15","author":"Hofmann H","year":"2017","unstructured":"Hofmann H, , Fingerle V, , Hunfeld KP, , Huppertz HI, et al. Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society. Ger Med Sci, 2017; 15:Doc14.","journal-title":"Ger Med Sci"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050381"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ttbdis.2014.09.004"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2710.210903"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/595427"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02862.x"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56030115"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01690092"},{"key":"e_1_3_6_21_1","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna Austria: R Foundation for Statistical Computing 2016. Available at: https:\/\/www.R-project.org"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874944501205010052"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.2807\/ese.16.27.19906-en"},{"key":"e_1_3_6_24_1","unstructured":"Robert Koch Institute. Epidemiologisches Bulletin. Case definitions communicable diseases for the ODG: Diseases for which according to the LVO an extended reporting obligation in addition to the IFSG (as of 2009) [in German]. 2009. Available at: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2009\/Ausgaben\/05_09"},{"key":"e_1_3_6_25_1","unstructured":"Robert Koch Institute. Notifiable diseases and pathogens [in German]. 2017. Available at: https:\/\/www.rki.de\/DE\/Content\/Infekt\/IfSG\/Meldepflichtige_Krankheiten\/Meldepflichtige_Krankheiten_Erreger.pdf?__blob=publicationFile"},{"key":"e_1_3_6_26_1","unstructured":"Robert Koch Institute. SurvStat@RKI 2.0. 2021a. Available at: https:\/\/survstat.rki.de"},{"key":"e_1_3_6_27_1","unstructured":"Robert Koch Institute. Survstat@RKI 2.0 General Information. 2021b. Available at: https:\/\/survstat.rki.de\/Content\/Instruction\/Content.aspx#merkm"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2308.161273"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.11.1800134"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10393-015-1034-3"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare7020066"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.5365\/wpsar.2012.3.3.001"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03175.x"},{"key":"e_1_3_6_34_1","first-page":"493","article-title":"Clinical and epidemiological findings for patients with erythema migrans. Comparison of cohorts from the years 1993 and 2000","volume":"114","author":"Strle F","year":"2002","unstructured":"Strle F, , Videcnik J, , Zorman P, , Cimperman J, et al. Clinical and epidemiological findings for patients with erythema migrans. Comparison of cohorts from the years 1993 and 2000. Wien Klin Wochenschr, 2002; 114:493\u2013497.","journal-title":"Wien Klin Wochenschr"},{"key":"e_1_3_6_35_1","unstructured":"The Federal Health Reporting Information System. Federal Health Reporting. Lyme Borreliosis\u2014Diagnostic data of the hospitals. 2021. Available at: www.gbe-bund.de"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780131009"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700160"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2101.140009"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ttbdis.2013.10.010"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1927.10502953"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115226"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8121859"}],"container-title":["Vector-Borne and Zoonotic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/vbz.2022.0046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/vbz.2022.0046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/vbz.2022.0046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:02:06Z","timestamp":1777590126000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/vbz.2022.0046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1089\/vbz.2022.0046"],"URL":"https:\/\/doi.org\/10.1089\/vbz.2022.0046","relation":{},"ISSN":["1530-3667","1557-7759"],"issn-type":[{"value":"1530-3667","type":"print"},{"value":"1557-7759","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}